JP3618736B2 - トロンビン由来ペプチドを使用した治療法 - Google Patents

トロンビン由来ペプチドを使用した治療法 Download PDF

Info

Publication number
JP3618736B2
JP3618736B2 JP2002508462A JP2002508462A JP3618736B2 JP 3618736 B2 JP3618736 B2 JP 3618736B2 JP 2002508462 A JP2002508462 A JP 2002508462A JP 2002508462 A JP2002508462 A JP 2002508462A JP 3618736 B2 JP3618736 B2 JP 3618736B2
Authority
JP
Japan
Prior art keywords
gly
asp
ala
pro
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002508462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004502739A (ja
JP2004502739A5 (enExample
Inventor
カーニー，ダレル，エイチ．
Original Assignee
ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム filed Critical ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム
Publication of JP2004502739A publication Critical patent/JP2004502739A/ja
Publication of JP2004502739A5 publication Critical patent/JP2004502739A5/ja
Application granted granted Critical
Publication of JP3618736B2 publication Critical patent/JP3618736B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Immunology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
JP2002508462A 2000-07-12 2001-07-12 トロンビン由来ペプチドを使用した治療法 Expired - Fee Related JP3618736B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21758300P 2000-07-12 2000-07-12
PCT/US2001/021944 WO2002004008A2 (en) 2000-07-12 2001-07-12 Methods of therapy with thrombin derived peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004232356A Division JP2005036007A (ja) 2000-07-12 2004-08-09 トロンビン由来ペプチドを使用した治療法

Publications (3)

Publication Number Publication Date
JP2004502739A JP2004502739A (ja) 2004-01-29
JP2004502739A5 JP2004502739A5 (enExample) 2005-01-06
JP3618736B2 true JP3618736B2 (ja) 2005-02-09

Family

ID=22811661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002508462A Expired - Fee Related JP3618736B2 (ja) 2000-07-12 2001-07-12 トロンビン由来ペプチドを使用した治療法
JP2004232356A Withdrawn JP2005036007A (ja) 2000-07-12 2004-08-09 トロンビン由来ペプチドを使用した治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004232356A Withdrawn JP2005036007A (ja) 2000-07-12 2004-08-09 トロンビン由来ペプチドを使用した治療法

Country Status (10)

Country Link
US (5) US6867190B2 (enExample)
EP (1) EP1253937B1 (enExample)
JP (2) JP3618736B2 (enExample)
CN (1) CN100500211C (enExample)
AT (1) ATE249238T1 (enExample)
AU (2) AU2001278907B2 (enExample)
CA (1) CA2415778A1 (enExample)
DE (2) DE60100740T4 (enExample)
TW (1) TWI257307B (enExample)
WO (1) WO2002004008A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
AU2002241917B2 (en) * 2000-07-12 2006-06-15 The Board Of Regents, The University Of Texas System Thrombin derived peptides for promoting cardiac tissue repair
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
US7803149B2 (en) * 2002-07-12 2010-09-28 Cook Incorporated Coated medical device
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
CA2511223A1 (en) * 2002-01-16 2003-07-31 The Board Of Regents, The University Of Texas System Thrombin derived peptides for promoting cardiac tissue repair
AU2003256343B2 (en) * 2002-07-02 2006-12-21 Orthologic Corp. Thrombin peptide derivatives
EP1539800B1 (en) * 2002-07-02 2007-05-23 Orthologic Corp. Thrombin peptide derivative dimers
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
AU2004211592B2 (en) 2003-02-12 2008-04-10 Monsanto Technology Llc Cotton event MON 88913 and compositions and methods for detection thereof
US8383158B2 (en) * 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
DE602004005564T2 (de) * 2003-12-31 2007-12-13 Orthologic Corp., Tempe Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten
CA2576971A1 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
JP2006321740A (ja) * 2005-05-18 2006-11-30 Kanazawa Univ 虚血後血管新生促進剤
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
CA2663547C (en) * 2006-09-22 2020-08-25 Orthologic Corp. Method of treating endothelial dysfunction
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
EP2155236A1 (en) * 2007-04-10 2010-02-24 The Board of Regents,The University of Texas System Combination therapy for cardiac revascularization and cardiac repair
US8202528B2 (en) * 2007-06-05 2012-06-19 Abbott Cardiovascular Systems Inc. Implantable medical devices with elastomeric block copolymer coatings
GB2450747A (en) * 2007-07-06 2009-01-07 Univ Sheffield Treatment of sensorineural hearing loss
US8586398B2 (en) * 2008-01-18 2013-11-19 Miasole Sodium-incorporation in solar cell substrates and contacts
AU2009229395A1 (en) * 2008-03-26 2009-10-01 The Board Of Regents, The University Of Texas System Method of treating degenerative diseases
US20110117075A1 (en) * 2008-03-26 2011-05-19 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
EP2268304A2 (en) * 2008-03-26 2011-01-05 Orthologic Corp. Methods for treating acute myocardial infarction
WO2009120307A2 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
US20110319340A1 (en) * 2008-09-19 2011-12-29 The Board Of Regents, The University Of Texas System Methods for treating cancer
US20130101574A1 (en) * 2010-06-11 2013-04-25 Darrell H. Carney Methods of using thrombin peptide derivatives
GB201314312D0 (en) * 2013-08-09 2013-09-25 Regentec Ltd Composition and delivery system
US20160039876A1 (en) 2014-03-28 2016-02-11 Claresa Levetan Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide
US10220078B2 (en) 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma
WO2020210087A1 (en) * 2019-04-12 2020-10-15 Affirmed Pharma, Llc Rusalatide acetate compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5244460A (en) * 1991-11-27 1993-09-14 The United States Of America As Represented By The Department Of Health And Human Services Method to foster myocardial blood vessel growth and improve blood flow to the heart
EP0697883A1 (en) 1993-04-29 1996-02-28 Washington University Use of platelet-derived growth factor to improve collateral circulation
ATE273322T1 (de) * 1995-10-24 2004-08-15 Chemo Sero Therapeut Res Inst Tfpi-verwandte peptide die das wachstums von glatten muskelzellen inhibieren
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
US6197751B1 (en) * 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
US6033436A (en) * 1998-02-17 2000-03-07 Md3, Inc. Expandable stent
JP2002512200A (ja) 1998-04-17 2002-04-23 アンジオジェニックス， インコーポレイテッド 治療的な脈管形成因子およびその使用方法
CA2340593C (en) 1998-10-26 2012-05-08 Kari Alitalo Use of vegf-c or vegf-d gene or protein to prevent restenosis
US6363938B2 (en) * 1998-12-22 2002-04-02 Angiotrax, Inc. Methods and apparatus for perfusing tissue and/or stimulating revascularization and tissue growth
TWI257307B (en) * 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair

Also Published As

Publication number Publication date
DE60100740D1 (de) 2003-10-16
TWI257307B (en) 2006-07-01
CN1455678A (zh) 2003-11-12
JP2004502739A (ja) 2004-01-29
CN100500211C (zh) 2009-06-17
EP1253937A2 (en) 2002-11-06
AU7890701A (en) 2002-01-21
HK1060302A1 (zh) 2004-08-06
WO2002004008A2 (en) 2002-01-17
US7034001B2 (en) 2006-04-25
AU2001278907B2 (en) 2004-10-21
US6867190B2 (en) 2005-03-15
US20060134167A1 (en) 2006-06-22
WO2002004008A3 (en) 2002-08-22
US6861407B2 (en) 2005-03-01
US20050153884A1 (en) 2005-07-14
US20080131474A1 (en) 2008-06-05
DE60100740T4 (de) 2005-01-27
DE60100740T2 (de) 2004-07-01
US7214661B2 (en) 2007-05-08
EP1253937B1 (en) 2003-09-10
US20020061852A1 (en) 2002-05-23
US20020187933A1 (en) 2002-12-12
JP2005036007A (ja) 2005-02-10
US7732411B2 (en) 2010-06-08
CA2415778A1 (en) 2002-01-17
ATE249238T1 (de) 2003-09-15

Similar Documents

Publication Publication Date Title
JP3618736B2 (ja) トロンビン由来ペプチドを使用した治療法
AU2001278907A1 (en) Methods of therapy with thrombin derived peptides
Patel et al. Angiogenesis with biomaterial-based drug-and cell-delivery systems
JP3639593B2 (ja) 塩基性線維芽細胞増殖因子含有架橋ゼラチンゲル製剤
EP1250166B1 (en) Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
US20060115457A1 (en) Biocompatible hydrogel compositions
JP5964369B2 (ja) 再狭窄の予防または治療のための化合物および方法
Yang et al. Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation
JP4205592B2 (ja) 心臓組織修復を促進するためのトロンビン由来ペプチド
CA2485268A1 (en) Resorbable pharmaceutical formulation for the continuous release of thrombin
KR20030068585A (ko) 혈관 증식을 억제하는 약제학적 조성물 및 그의 이용 방법
AU2002241917B2 (en) Thrombin derived peptides for promoting cardiac tissue repair
HK1060302B (en) Methods of therapy with thrombin derived peptides
AU2002241917A1 (en) Thrombin derived peptides for promoting cardiac tissue repair
HK1078263B (en) Thrombin derived peptides for promoting cardiac tissue repair
TAXI et al. Jamila CHEDLY1, Sylvia SOARES1, Alexandra MONTEMBAULT2, Ysander von BOXBERG1, Michèle VERON-RAVAILLE1, Christine MOUFFLE1, Marie-Noelle BENASSY1

Legal Events

Date Code Title Description
A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040430

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20040611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040810

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20040914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20041018

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20041110

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081119

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091119

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091119

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101119

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111119

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121119

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121119

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131119

Year of fee payment: 9

LAPS Cancellation because of no payment of annual fees